Back
Revance Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
RVNC
Sponsored
Yours Free! Top SIX AI Dividend Stocks Right Now
NO CREDIT CARD REQUIRED!
Sell
13
RVNC
Revance Therapeutics
Last Price:
3.71
Seasonality Move:
7.02%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE TradeRevance Therapeutics Price Quote
$3.71
+0.00 (+-35.81%)
(Updated: November 9, 2024 at 5:44 AM ET)
Revance Therapeutics Key Stats
Sell
13
Revance Therapeutics (RVNC)
is a Sell
Day range:
$3.48 - $4.34
52-week range:
$2.30 - $9.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.40
P/B ratio:
0%
Volume:
13M
Avg. volume:
2M
1-year change:
-55.52%
Market cap:
$386M
Revenue:
$234M
EPS:
$-3.2
How Much Does Revance Therapeutics Make?
-
How Much Are Revance Therapeutics's Sales Annually?
RVNC Revenues are $234M -
How Much Profit Does Revance Therapeutics's Make A Year?
RVNC net income is -$324M
Is Revance Therapeutics Growing As A Company?
-
What Is Revance Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.2% -
What Is Revance Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Revance Therapeutics Stock Price Performance
-
Did Revance Therapeutics Stock Go Up Last Month?
Revance Therapeutics share price went down by -29.02% last month -
Did RVNC's Share Price Rise Over The Last Year?
RVNC share price fell by -55.52% over the past 1 year
What Is Revance Therapeutics 52-Week High & Low?
-
What Is Revance Therapeutics’s 52-Week High Share Price?
Revance Therapeutics has traded as high as $9.75 over the past 52 weeks -
What Is Revance Therapeutics’s 52-Week Low Share Price?
Revance Therapeutics has traded as low as $2.30 over the past 52 weeks
Revance Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Revance Therapeutics?
-
How Much Debt Does Revance Therapeutics Have?
Total long term debt quarterly is $430.6M -
How Much Cash Does Revance Therapeutics Have?
Cash and short term investments quarterly total is $232.2M -
What Is Revance Therapeutics’s Book Value Per Share?
Book value per share is -1.24
Is Revance Therapeutics Cash Flow Positive?
-
What Is RVNC Cash Flow From Operations?
Cash flow from operations (TTM) is -$200.8M -
What Is Revance Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $125.2M -
What Is Revance Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $15.4M
Revance Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
RVNC return on invested capital is -87.72% -
What Is Revance Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -55.05% -
What Is RVNC Return On Equity?
ROE is a measure of profitability and is 0%
Revance Therapeutics Earnings Date & Stock Price
-
What Is Revance Therapeutics's Stock Price Today?
A single share of RVNC can be purchased today for 3.71 -
What Is Revance Therapeutics’s Stock Symbol?
Revance Therapeutics trades on the nasdaq under the ticker symbol: RVNC -
When Is Revance Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Revance Therapeutics is scheduled on February 28, 2025 -
When Is RVNC's next ex-dividend date?
Revance Therapeutics's next ex-dividend date is May 15, 2020 -
How To Buy Revance Therapeutics Stock?
You can buy Revance Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Revance Therapeutics Competitors
-
Who Are Revance Therapeutics's Competitors?
Below is a list of companies who compete with Revance Therapeutics or are related in some way:
Revance Therapeutics Dividend Yield
-
What Is RVNC Dividend Yield?
Revance Therapeutics’s dividend yield currently is 0% -
What Is Revance Therapeutics’s Payout Ratio?
Revance Therapeutics’s payout ratio is 0% -
When Did Revance Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 10, 2024 -
What Is Revance Therapeutics’s Dividend Per Share?
Revance Therapeutics pays a dividend of $0.00 per share
Revance Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 6.33% |
Revenue: | 20.17% | -12.17% |
Analyst Recommendations
Buy Recommendations: | 1 |
---|---|
Hold Recommendations: | 8 |
Sell Recommendations: | 0 |
Price Target: | 9.23 |
Upside from Last Price: | 149.01% |